Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

Inclusion Criteria

• •Subject is an infant born to a mother who was exposed to study drug on a tanezumab clinical study.
• •The infant's mother (who was the tanezumab clinical study participant) must review, agree and sign an informed consent document explaining the details of the perinatal and post natal follow up. Where local regulations mandate, the male parent would also review and sign the informed consent.
• •Parents or legal guardian must be willing and able to comply with scheduled visits and study procedures.